References
- 1. Covid-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022; 399: 1513–1536. doi.org/10.1016/S0140-6736(21)02796-3.
- 2. Delardas O., Kechagias K.S., Pontikos P.N., Giannos P. (2022) Socio-Economic Impacts and Challenges of the Coronavirus Pandemic (COVID-19): An Updated Review. Sustainability, 14. doi.org/10.3390/su14159699.
- 3. Doroftei B., Ciobica A., Ilie O.D. et al. (2021) Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics (Basel), 11. doi.org/10.3390/diagnostics11040579.
- 4. www.worldometers.info/coronavirus/worldwide-graphs/.
- 5. Astin R., Banerjee A., Baker M.R. et al. (2023) Long COVID: mechanisms, risk factors and recovery. Exp. Physiol., 108: 12–27. doi.org/10.1113/EP090802.
- 6. Gyongyosi M., Alcaide P., Asselbergs F.W. et al. (2022) Long COVID and the cardiovascular system — elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial & Pericardial Diseases. Cardiovasc. Res. doi.org/10.1093/cvr/cvac115.
- 7. NICE (2022) COVID-19 rapid guideline: managing the long-term effects of COVID-19. In: COVID-19 rapid guideline: managing the long-term effects of COVID-19.
- 8. Tran V.T., Porcher R., Pane I., Ravaud P. (2022) Course of post COVID-19 disease symptoms over time in the ComPaRe long COVID prospective e-cohort. Nat. Commun., 13: 1812. doi.org/10.1038/s41467-022-29513-z.
- 9. Carfi A., Bernabei R., Landi F. et al. (2020) Persistent Symptoms in Patients After Acute COVID-19. JAMA, 324: 603–605. doi.org/10.1001/jama.2020.12603.
- 10. World Health Organization (WHO) (2021) COVID-19 Clinical management: living guidance, 25.01.2021. http://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.
- 11. Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med., 166: 111–117. doi.org/10.1164/ajrccm.166.1.at1102.
- 12. Mahler D.A., Wells C.K. (1988) Evaluation of clinical methods for rating dyspnea. Chest, 93: 580–586. doi.org/10.1378/chest.93.3.580.
- 13. Jones P.W., Harding G., Berry P. et al. (2009) Development and first validation of the COPD Assessment Test. Eur. Respir. J., 34: 648–654. doi.org/10.1183/09031936.00102509.
- 14. van der Molen T., Willemse B.W., Schokker S. et al. (2003) Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes, 1: 13. doi.org/10.1186/1477-7525-1-13.
- 15. Sorensen A.I.V., Spiliopoulos L., Bager P. et al. (2022) A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. Nat. Commun., 13: 4213. doi.org/10.1038/s41467-022-31897-x.
- 16. Hughes S.E., Haroon S., Subramanian A. et al. (2022) Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BM, 377: e070230. doi.org/10.1136/bmj-2022-070230.